Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain
the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in
Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles
and JavaScript.
Too many cancer therapies target the same pathways. So say the founders of two cancer-focused biotech start-ups that got their footing last year. Case in point: of the six approved chimeric antigen receptor (CAR)-T therapies, four target the same molecule (CD-19), and the other two target another blood-related antigen (BCMA). But now Cartography Biosciences and Nested Therapeutics believe they have pathways to better targets. Both companies are delving into large databases of cancer mutations to find targets in proteins or pathways that have either escaped detection or have been ignored because they are present at too low a frequency. Each company has a distinct strategy to reach their goal of finding these diamonds in the rough. Cartography board member Jorge Conde, a general partner at Andreessen Horowitz, which was an early investor in the company, says, “We have a lot of really great tools in terms of therapeutics; what we have shortage of is novel targets against which we can direct those tools.”
